Sun Pharma

Sun Pharmaceutical Industries Limited
Company typePublic
ISININE044A01036
IndustryPharmaceuticals
Founded1983 (1983)
FounderDilip Shanghvi
Headquarters,
India
Area served
Worldwide
Key people
Dilip Shanghvi (MD)
Products
Revenue 52,578 crore (US$6.2 billion) (2025)
15,271 crore (US$1.8 billion) (2025)
11,984 crore (US$1.4 billion) (2025)
Total assets 92,100 crore (US$11 billion) (2025)
Total equity 72,485 crore (US$8.6 billion) (2025)
OwnerDilip Shanghvi family (54.48%)
Number of employees
41,000+ (2023)
Websitesunpharma.com
Footnotes / references
Financials as of 31 March 2025.[1][2]

Sun Pharmaceutical Industries Limited (d/b/a Sun Pharma) is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries.[3] It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.[4][5]

Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover.[6] Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe.[7] The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals.[4] Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin.[8]

  1. ^ "Sun Pharma reports Q4 and full year results for FY25" (PDF). Sun Pharma. Retrieved 24 May 2025.
  2. ^ "Statement of Audited Consolidated Financial Results for the Quarter and Year ended March 31, 2025" (PDF). Sun Pharma. Retrieved 24 May 2025.
  3. ^ Banerjee, Avishek. "Sun Pharma: Global Is Local". BW Businessworld. Archived from the original on 26 July 2022. Retrieved 13 November 2022.
  4. ^ a b "Sun Pharmaceuticals Industries Ltd". Business Standard India. Archived from the original on 9 August 2022. Retrieved 13 November 2022.
  5. ^ "Sun Pharma Industries". Forbes. Archived from the original on 23 September 2022. Retrieved 13 November 2022.
  6. ^ "US business remains Sun Pharma's weak spot". www.fortuneindia.com. 10 November 2017. Retrieved 6 August 2021.
  7. ^ "Creating Lasting Value Investor Presentation - February 2014" (PDF). Archived from the original (PDF) on 13 April 2014. Retrieved 10 April 2014.
  8. ^ "Sun Pharmaceutical Industries Ltd: Profile, Pharma Products, History...IBEF". India Brand Equity Foundation. Archived from the original on 24 May 2022. Retrieved 13 November 2022.